Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 6.5%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price was up 6.5% during mid-day trading on Wednesday . The company traded as high as $14.21 and last traded at $14.07. Approximately 178,313 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 349,272 shares. The stock had previously closed at $13.21.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on YMAB shares. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Truist Financial began coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 price objective on the stock. Morgan Stanley reduced their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, BMO Capital Markets reduced their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Trading Up 6.6 %

The stock has a market cap of $617.87 million, a PE ratio of -28.71 and a beta of 0.70. The company has a fifty day moving average of $12.95 and a 200-day moving average of $13.26.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The firm had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same quarter in the prior year, the firm posted ($0.14) EPS. As a group, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock valued at $1,338,100 in the last three months. 21.50% of the stock is owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in YMAB. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $562,000. Squarepoint Ops LLC boosted its position in shares of Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the period. Millennium Management LLC boosted its position in shares of Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Boston Partners acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at about $556,000. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.